Methods
Our study was a multicenter, double-blind, randomized trial conducted at eight clinical sites of the T1D Exchange Clinic Network as a preplanned substudy of a larger metformin trial with the primary outcome of change in HbA1c. Detailed methods from the parent study have already been published (31) . The protocol was approved by local Institutional Review Boards. Written informed consent was obtained from participants aged 18 years and older or from a parent or guardian for younger participants who also assented. Study oversight was provided by an independent data and safety monitoring committee. The number of participants per site were as follows: University of Colorado Anschutz Medical Campus, 11; Yale University, 6; Nemours Children's Specialty Care, 3; Indiana University, 5; University of Minnesota, 3; University of Iowa, 6; Children's Hospital of Pittsburgh, 3.
Study participants
Major inclusion criteria included presumed autoimmune type 1 diabetes (diagnosis prior to age 10 years and/or positive diabetes-related autoantibodies) for at least 1 year treated on either an insulin pump or three or more daily injections of insulin, age of 12 to ,20 years, HbA1c 7.5% to 9.9% (58 to 85 mmol/mol), BMI $85th percentile for age and sex, total daily insulin dose (TDI) of $0.8 U/kg/d, and frequency of self-monitoring of blood glucose three or more times per day. Fasting C-peptide was undetectable in 26 participants, ,0.3 nmol/L in an additional 10 participants, and was equal to 1 nmol/L in one participant.
Treatment
Each participant was randomly assigned using a computergenerated sequence to either metformin or placebo with equal probability using a permuted block design. A central pharmacy compounded the placebo to match the 500-mg metformin tablets. Study medication was titrated during 4 weeks up to 1000 mg twice daily for the remainder of the 3-month treatment period. Study drug dosage could be titrated at a slower rate and/or adjusted due to adverse effects per investigator discretion. Clinician judgment was used to adjust insulin doses. Pill counts of bottles returned by study participants were used to assess compliance. All adverse events were reported regardless of whether the event was considered treatment-related and coded using the Medical Dictionary for Regulatory Activities. Reportable severe hypoglycemia was defined as low blood glucose requiring assistance of another person to administer carbohydrate, glucagon, or other resuscitative actions to treat altered consciousness. dosages, and to assess for adverse events. An interim office visit was conducted after 6 weeks of study drug therapy.
Study procedures and assessments
At baseline and 12 weeks, height, weight, blood pressure, waist circumference, and TDI/kg of participants were assessed; Tanner staging was performed at randomization (pubic hair for both sexes, breasts for girls, genitalia for boys); dual-energy x-ray absorptiometry scans were performed to assess body composition.
Participants were admitted to the inpatient clinical translational research center for 12 hours of overnight monitored fasting and overnight glucose control. Subcutaneous insulin was replaced with a variable-rate algorithm-driven overnight IV insulin infusion to normalize blood sugar concentrations (goal of 100 mg/dL). The last dose of medication (metformin or placebo) was given in the hospital, the night prior to the clamp. The following morning, fasting blood samples to measure background enrichment and concentrations of glucose and glycerol were obtained. /min insulin phase, and a 2-hour 80 mU/m 2 /min insulin phase) hyperinsulinemic euglycemic clamp was performed (7, 16) to assess adipose, hepatic, and peripheral IR. Insulin doses were based on ours and others' (7, 16, 20) 
Sample analysis
All tracer samples were analyzed at the University of Colorado. Analysis of glycerol and glucose were performed using gas chromatography-mass spectrometry as described (18, 33, 35) . Serum laboratory analyses were performed at a central laboratory (Northwest Lipid Research Laboratories, University of Washington, Seattle, WA) for HbA1c (automated glycohemoglobin analyzer HLC-723G8, Tosoh Bioscience, San Francisco, CA), FFA (Wako Diagnostics, Richmond, VA) on a Roche Modular P autoanalyzer (Roche Diagnostics, Indianapolis, IN), and insulin concentrations (two-site immune-enzymometric assay performed on the Tosoh 2000 autoanalyzer (Tosoh Bioscience).
All isotopic enrichments were corrected for background enrichments. The glucose and glycerol rate of appearance (Ra), rate of disappearance (Rd), and metabolic clearance rate (MCR) during the last 30 minutes of each clamp phase were calculated using Steele non-steady-state equations, accounting for "spiked" glucose in the 20% dextrose infusion (18) . To describe changes in Ra across the insulin concentrations of each phase, the intercept and slope of the log-transformed regression line for each individual's data were also used to calculate the predicted glycerol and glucose Ra at the average insulin concentration for all participants during the 16 mU/m 2 /min phase (36) .
Outcomes
The primary analysis was treatment group comparison of mean change in GIR (mg/kg/min) at 13 weeks, adjusted for baseline GIR using analysis of covariance and an intent-to-treat approach. Multiple imputation using Rubin's method, in which each missing value is imputed multiple times and the resulting data sets are combined per standard procedures, was used to impute missing IR outcomes. The primary analysis was repeated without imputation and compared with the results using imputation in a sensitivity analysis.
Statistical analysis
Descriptive statistics are presented as mean 6 SD, median (Q1, Q3), or frequencies and percentages, as appropriate. For single time point variables, group comparisons were made using a x 2 or Fisher's exact test and the t test or Kruskal-Wallis test.
Repeated-measures mixed models compared outcomes measured at multiple time points during the clamp. The repeatedmeasures models for glucose and insulin contained terms for group (type 1 diabetes or control), clamp phase, and the interaction of group and phase. For repeated-measures outcomes (glucose Ra, glycerol Ra, glycerol, FFAs) potentially impacted by serum insulin concentrations, insulin was added to the model and the Aikaike information criterion, an estimate of model fit to a particular set of data, was used to test whether a random effect of insulin should be included (37) . The three-way interactions of group, phase, and insulin were tested for significance, but all twoway interactions were retained in the models. For glucose Ra, glycerol Ra, and insulin concentrations, there were two repeat factors: phase of the clamp (basal, 16 mU/m 2 /min, and 80 mU/ m 2 /min phase) and visit (baseline and 13 weeks). Nested repeated mixed models were used to assess for significant differences in the change in glucose Ra and glycerol Ra from baseline to 13 weeks between treatment groups. To accommodate nested repeated measures data, a model with a composite Kronecker product covariance structure, which essentially combines two types of covariance matrices, accounted for the separate covariance structures for each repeat factor (phase of clamp, visit).
P values ,0.05 were considered significant for main effects; P values ,0.25 were considered significant for interactions. All statistical analyses were performed with SAS software, version 9.4 (SAS Institute, Cary, NC).
Results
Thirty-seven youth with type 1 diabetes were randomized to either 3 months of metformin (N 5 19) or placebo (N 5 18) in addition to their insulin therapy (Table 1) . Table 2 displays adverse events by treatment group. Side effects were minimal and were limited to gastrointestinal symptoms, which did not differ between groups, and to one episode of diabetic ketoacidosis in the metformin group. No participants experienced severe hypoglycemia.
The two groups were similar for age, sex, race/ethnicity, Tanner stage, weight, lean mass, BMI percentile, BMI z score, TDI/kg, and GIR (Table 1) . At 6 weeks, all participants reported taking at least 1500 mg a day in the metformin group. By 13 weeks, one of the metformin participants discontinued medication, and a second reported taking only 1000 mg a day. All participants in the metformin group and 16 of 18 in the placebo group completed the final visit ( Fig. 1 ).
Baseline clamp assessments
By design, the glucose concentrations throughout the three clamp phases were similar between groups ( Fig. 2A) . The insulin concentrations (Fig. 2B ) increased in both groups with the administration of increasing doses of insulin and were similar between groups. Owing to the significant insulin requirements to maintain glycemia overnight, resulting insulin concentrations at the initial AM basal phase were similar to those achieved at the 16 mU/m 2 /min phase.
Glucose Ra ( Change between groups with intervention Change in body weight and BMI z score were significantly different between groups postintervention ( Table 3 ). The groups were not different postintervention Fig. 4D ) and favored metformin. The posttreatment change in glucose Ra during the 16 mU/m 2 /min phase representing hepatic insulin sensitivity (Fig. 4E) was not significantly different between groups (P 5 0.12). The change in glycerol Ra (Fig. 2F) , representing adipose insulin sensitivity, was not different (P 5 0.69). Table 4 shows the results of the repeated-measures mixed models for glucose and glycerol Ra. The leastsquares estimate is the estimated difference between groups in the change in the outcome from baseline to week 13, at the overall group mean insulin concentration during each phase. There were no significant differences between the groups in either the change in glycerol Ra or glucose Ra during any of the stages postintervention.
Discussion
We previously established that IR is present in the muscle, liver, and adipose tissue in adolescents with type 1 diabetes (19) . We also previously reported in a large cohort of youth who were overweight/obese with type 1 diabetes that despite no change in HbA1c, 6 months of adjunctive metformin decreased BMI, adiposity, and TDI/kg, suggesting improved insulin sensitivity. We now demonstrate in a subgroup of the same study, utilizing gold-standard measures of tissue-specific insulin sensitivity, the novel finding that 3 months of metformin significantly improved whole-body and related peripheral insulin sensitivity in youth who were overweight/ obese with type 1 diabetes. We also now show, to our knowledge for the first time, that metformin does not significantly improve the abnormal failure of suppression of EGP in this population. Although not directly compared in the same study, we also report a greater degree of muscle IR in youth who were overweight/obese with type 1 diabetes than that previously reported in normal-weight youth with type 1 diabetes, yet a similar degree of hepatic IR (16, 19) . Furthermore, owing to high insulin requirements to control overnight glycemia, adipose IR was unable to be fully assessed by traditional methods in the adolescent population with obesity with type 1 diabetes, as fasting glycerol Ra was suppressed.
Most metformin studies in individuals with type 1 diabetes, including two pediatric studies (31, 32) and a Cochrane Systematic Review (38) , found that metformin decreases TDI and BMI with no improvement in HbA1c, suggesting improved insulin sensitivity. A smaller study in Swedish adolescents found a significant improvement in whole-body IR within 11 participants in the metformin group (39) . However, this study used a lower insulin clamp dose than typical for adolescents and a brief insulin infusion, lacked overnight glucose control, was not powered to compare effects between metformin and placebo and did not focus on participants who were overweight/obese (39) . Our data now demonstrate that metformin improves whole-body IR in adolescents who are overweight/obese with type 1 diabetes and adds the novel finding of specifically improving peripheral IR in this population. Altered muscle mitochondrial function, pubertal hormones, and unknown factors unique to type 1 diabetes, confounded by obesity and obesity-related hormones, likely play a role in the significant peripheral IR found in our participants (16, 19) . We previously demonstrated decreased repletion of ATP from ADP following exercise in normal-weight youth with diabetes, and this mitochondrial dysfunction related to peripheral IR (17) . Pubertal changes in growth hormone and sex steroids also contribute to the unique IR seen in adolescents (40) . Whereas more extreme hyperglycemia typical in historic diabetes therapy related to IR, we showed that in an HbA1c range more consistent with modern therapies, similar to the youth now presented, hyperglycemia did not explain the whole-body IR (20, 41) . Alternations in blood flow, insulin diffusion across blood vessels and epithelial layers, elevated FFAs from adipose IR, and nonphysiologic mode of insulin delivery are other likely contributors (42) . Obesity is also a wellestablished cause of peripheral IR and likely worsens the IR of type 1 diabetes, potentially secondary to excess influx of FFAs, adipose-related inflammatory cytokines, and hormones such as leptin (19, 42) . Further research is needed to completely understand peripheral IR in type 1 diabetes. The cause of persistent EGP during hyperinsulinemia in adolescents with type 1 diabetes is likely multifactorial and potentially related to hepatic IR, lack of portal insulin delivery secondary to peripheral insulin administration, insulin omission, and/or altered a-cell function/ glucagon release. Normally significant hepatic extraction of secreted insulin occurs via the portal circulation and likely meditates EGP prior to entering the peripheral circulation, but this process is bypassed with peripheral delivery of insulin (43, 44) . Furthermore, glucagon secretion is altered in type 1 diabetes, likely secondary to lack of paracrine effects of secreted insulin and primary loss of a-cells (43, 44) , and may contribute to persistent hepatic EGP. Alterations in pancreatic and hepatic insulin delivery due to decreased pancreatic and/or portal blood flow may also impact EGP (45) . Thus, multiple factors might explain why EGP was similarly not suppressed by peripheral hyperinsulinemia between previously published normal weight youth and our current cohort of youth who were overweight, and was not affected by metformin therapy.
In youth who were overweight/obese with type 1 diabetes, we were unable to show whether metformin therapy improved adipose IR. Although we were not able to fully model suppression of lipolysis with glycerol Ra as discussed below, neither glycerol nor FFA concentrations decreased following metformin therapy during any phase Cree
between palmitoleic acid and IR, indicating that mechanisms of adipose IR in type 1 diabetes may be unique (35) . Adipose IR in type 1 diabetes requires further investigation, including local tissue effects. Owing to the extreme peripheral IR in our adolescent population with obesity and type 1 diabetes, performance of clamp studies to assess hepatic and adipose IR were challenging. For the assessment of adipose IR, glycerol and FFA concentrations were already partially suppressed during the basal phase. Compared with normal-weight youth or adults with type 1 diabetes who underwent protocols similar to our current study, basal glycerol and FFA concentrations were lower in our those who were overweight/obese with type 1 diabetes (18, 19, 35) . Similarly, glycerol Ra was already suppressed in the basal state in those who were overweight/obese, a finding not present in our normal-weight type 1 group (19), indicating that the high overnight insulin requirements suppressed lipolysis before starting the clamp. These findings suggest that the reduction in peripheral insulin sensitivity that occurs when overweight/obesity is superimposed on adolescent type 1 diabetes is extreme, making traditional adipose IR methods uninterpretable. In contrast, the basal glucose Ra in members of our population who were overweight/obese with type 1 diabetes was similar to our previous normal-weight population, indicating that overweight/obesity did not worsen the already existing hepatic IR in type 1 diabetes (19 The mechanisms of action of metformin are not fully understood, but its impacts on hepatic IR are typically thought to be primary. Metformin is thought to lower adenosine monophosphate, decrease gluconeogenesis, and inhibit the effect of glucagon (46) . A systematic review of 19 clinical studies investigating metformin's effect on endogenous glucose production in adults with type 2 diabetes used similar methodology as the current study (47) . Results indicated that metformin primarily improved hepatic IR by enhancing insulin suppression of EGP and fasting plasma glucose clearance in this population. To a lesser degree, metformin increased insulin-stimulated glucose utilization; however, the estimated treatment-induced change in insulin-stimulated glucose utilization did not meet statistical significance in the pooled placebo-controlled studies. Our study population differs, as we performed investigations in adolescents with type 1 diabetes. Whole-body insulin sensitivity is known to be significantly lower in youth vs adults (48) , including youth with type 1 diabetes (16, 19), and, as a result, insulin requirements are dramatically higher than in adults (42) . The phenotype of IR in type 1 diabetes is also unique from type 2 diabetes, as many people with type 1 diabetes lack metabolic syndrome components despite being insulin resistant (7), which also may explain the different responses seen to metformin in our study vs those on type 2 diabetes. Moreover, the basal insulin delivery required to achieve fasting euglycemia was greater than expected in our population, and it may have limited our ability to assess some aspects of IR. Our study has several strengths. First, to our knowledge, it was the first multicenter, double-blind, randomized control trial of metformin in youth who were overweight/obese with type 1 diabetes with insulin sensitivity assessed using isotope tracers and a multiphase clamp. All of the sites included investigators and pharmacists who were trained in the performance of pediatric hyperinsulinemic clamps with tracers using standardized protocols to limit site-to-site variation, and overnight glucose control was performed with a centralized algorithm. The multicenter nature also allowed for greater geographic diversity. The overall reported adherence to medication and study procedures was excellent for a clinical trial, with a low dropout or discontinuation rate. Additionally, all isotope samples were processed in one central laboratory and all clinical laboratory assays were performed at a central laboratory.
The major limitation of our study was the relatively small sample size, which did not allow us to examine the effect of sex, ethnicity, or different home insulin regimens. A few of the secondary study measures, such as change in GDR, are close to significance, suggesting a possible type 2 error due to smaller sample size. Furthermore, the inclusion criteria were fairly strict in terms of HbA1c and weight, which may limit the generalizability of the results to a broader type 1 diabetes population. Moreover, the basal insulin requirements to control glycemia were so high in members of this population who were overweight/obese that the basal (overnight) insulin infusions were elevated enough to suppress glycerol and FFAs as discussed. Whereas improvement of insulin sensitivity was found at 13 weeks of metformin therapy, longer studies in adults indicate that metformin adherence wanes over time with a 26% discontinuation rate, which may limit the utility of this therapy, and thus longer-term studies are needed (15) .
In summary, we demonstrated that the addition of metformin to insulin therapy in youth who were overweight or obese with type 1 diabetes improves wholebody and specifically peripheral muscle IR during a 13-week period. However, alternative approaches are likely needed to target the hepatic IR of youth who are overweight/obese with type 1 diabetes. Moreover, new method development is needed in this population to assess adipose IR. Improvements in IR during metformin therapy have been tied to improvements in CVD risk markers in adults and youth with type 1 diabetes (15, 49) . Further work is now needed to determine whether this modified risk translates to long-term improvements in morbidity and mortality to warrant widespread use of metformin in youth who are obese with type 1 diabetes.
